Richard Gralla MD
Professor, Medicine, A Einstein Coll of Med of Yeshiva Univ
Join to View Full Profile
450 Lakeville RdNew Hyde Park, NY 11042
Phone+1 516-734-8900
Fax+1 516-734-8934
Are you Dr. Gralla?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Richard Gralla, MD is an oncologist in New Hyde Park, New York. He is currently licensed to practice medicine in New York and Louisiana. He is a Professor at A Einstein Coll of Med of Yeshiva Univ.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1974 - 1977
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1972 - 1974
University of Virginia School of MedicineClass of 1972
Certifications & Licensure
NY State Medical License 1974 - 2025
LA State Medical License 1990 - 2000
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- MASCC antiemetic consensus recommendations: resource-limited settings.Snezana M Bosnjak, Ana Zilic, Venkatraman Radhakrishnan, Vikas Ostwal, Matti Aapro
Supportive Care in Cancer. 2025-02-12 - 4 citations2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer pati...Samantha K F Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko
Supportive Care in Cancer. 2024-04-10 - 11 citationsEmetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport
Supportive Care in Cancer. 2023-12-22
Authored Content
- Evaluation of Health-Related Quality of Life and Symptoms in Patients withSeptember 2018
Press Mentions
5 Key Takeaways from Mesothelioma Expert TeleconferenceApril 9th, 2018
FDA Approves Rolapitant for CINVSeptember 2nd, 2015
